These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 32300936)

  • 41. Withdrawal of Immunomodulators or TNF Antagonists in Patients With Inflammatory Bowel Diseases in Remission on Combination Therapy: A Systematic Review and Meta-analysis.
    Katibian DJ; Solitano V; Polk DB; Nguyen T; Ma C; Syal G; Kobayashi T; Hibi T; Buhl S; Ainsworth MA; Jairath V; Singh S
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):22-33.e6. PubMed ID: 37716619
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hemophagocytic syndrome in a child with severe Crohn's disease and familial Mediterranean fever.
    Uslu N; Demir H; Balta G; Saltik-Temizel IN; Ozen H; Gürakan F; Yüce A
    J Crohns Colitis; 2010 Sep; 4(3):341-4. PubMed ID: 21122524
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [X-linked inhibitor of apoptosis deficiency manifested as Crohn's disease: a case report and literature review].
    Xu LJ; Luo YY; Yu JD; Lou JG; Fang YH; Chen J
    Zhonghua Er Ke Za Zhi; 2018 Jan; 56(1):43-47. PubMed ID: 29342997
    [No Abstract]   [Full Text] [Related]  

  • 46. Hemophagocytic Lymphohistiocytosis in Malignant Hematology: Uncommon but Should Not Be Forgotten?
    Roe C; Bennett J; Zhang L; Chavez J; Shah B; Sokol L; Komrokji R
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S147-50. PubMed ID: 26297268
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany.
    Classen JM; Muzalyova A; Nagl S; Fleischmann C; Ebigbo A; Römmele C; Messmann H; Schnoy E
    Dig Dis; 2022; 40(6):719-727. PubMed ID: 34915480
    [TBL] [Abstract][Full Text] [Related]  

  • 48. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
    Peyrin-Biroulet L; Rahier JF; Kirchgesner J; Abitbol V; Shaji S; Armuzzi A; Karmiris K; Gisbert JP; Bossuyt P; Helwig U; Burisch J; Yanai H; Doherty GA; Magro F; Molnar T; Löwenberg M; Halfvarson J; Zagorowicz E; Rousseau H; Baumann C; Baert F; Beaugerie L;
    Clin Gastroenterol Hepatol; 2023 Mar; 21(3):771-788.e10. PubMed ID: 36152897
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hemophagocytic lymphohistiocytosis as a harbinger of aggressive lymphoma: a case series.
    Pasvolsky O; Zoref-Lorenz A; Abadi U; Geiger KR; Hayman L; Vaxman I; Raanani P; Leader A
    Int J Hematol; 2019 May; 109(5):553-562. PubMed ID: 30850926
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Crohn's disease complicated by Epstein-Barr virus-driven haemophagocytic lymphohistiocytosis successfully treated with rituximab.
    Thompson G; Pepperell D; Lawrence I; McGettigan BD
    BMJ Case Rep; 2017 Feb; 2017():. PubMed ID: 28228435
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD.
    Moosvi Z; Duong JT; Bechtold ML; Nguyen DL
    South Med J; 2021 Feb; 114(2):98-105. PubMed ID: 33537791
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Case of Hemophagocytic Lymphohistiocytosis (HLH) Secondary to T Cell Lymphoma and Cytomegalovirus (CMV) Infection and Complicated by Tumor Lysis Syndrome (TLS).
    Kilani Y; Laxamana T; Mahfooz K; Yusuf MH; Perez-Gutierrez V; Shabarek N
    Am J Case Rep; 2022 Apr; 23():e935915. PubMed ID: 35361746
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A Review of Current and Emerging Therapeutic Options for Hemophagocytic Lymphohistiocytosis.
    Summerlin J; Wells DA; Anderson MK; Halford Z
    Ann Pharmacother; 2023 Jul; 57(7):867-879. PubMed ID: 36349896
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease.
    Choi YI; Kim TJ; Park DK; Chung JW; Kim KO; Kwon KA; Kim YJ
    Int J Colorectal Dis; 2019 Oct; 34(10):1713-1721. PubMed ID: 31471699
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials.
    Ben-Horin S; Novack L; Mao R; Guo J; Zhao Y; Sergienko R; Zhang J; Kobayashi T; Hibi T; Chowers Y; Peyrin-Biroulet L; Colombel JF; Kaplan GG; Chen MH
    Gastroenterology; 2022 Feb; 162(2):482-494. PubMed ID: 34757139
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Law CCY; Koh D; Bao Y; Jairath V; Narula N
    Inflamm Bowel Dis; 2020 Nov; 26(12):1796-1807. PubMed ID: 32047894
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
    Noseda R; Bertoli R; Müller L; Ceschi A
    J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
    Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P
    Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.
    Bonovas S; Fiorino G; Allocca M; Lytras T; Nikolopoulos GK; Peyrin-Biroulet L; Danese S
    Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1385-1397.e10. PubMed ID: 27189910
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.